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Objectives The aim of this study was to test the hypothesis that angiotensin (Ang)-converting enzyme-2 (ACE2) overexpres-
sion may inhibit myocardial collagen accumulation and improve left ventricular (LV) remodeling and function in
diabetic cardiomyopathy.
Background Hyperglycemia activates the renin-Ang system, which promotes the accumulation of extracellular matrix and
progression of cardiac remodeling and dysfunction.
Methods Ninety male Wistar rats were divided randomly into treatment (n  80) and control (n  10) groups. Diabetes
was induced in the treatment group by a single intraperitoneal injection of streptozotocin. Twelve weeks after
streptozotocin injection, rats in the treatment group were further divided into adenovirus-ACE2, adenovirus–
enhanced green fluorescent protein, losartan, and mock groups (n  20 each). LV volume; LV systolic and dia-
stolic function; extent of myocardial fibrosis; protein expression levels of ACE2, Ang-converting enzyme, and
Ang-(1-7); and matrix metalloproteinase–2 activity were evaluated. Cardiac myocyte and fibroblast culture was
performed to assess Ang-II and collagen protein expression before and after ACE2 gene transfection.
Results Four weeks after ACE2 gene transfer, the adenovirus-ACE2 group showed increased ACE2 expression, matrix metallo-
proteinase–2 activity, and LV ejection fractions and decreased LV volumes, myocardial fibrosis, and ACE, Ang-II, and
collagen expression in comparison with the adenovirus–enhanced green fluorescent protein and control groups.
ACE2 was superior to losartan in improving LV remodeling and function and reducing collagen expression. The puta-
tive mechanisms may involve a shift in balance toward an inhibited fibroblast-myocyte cross-talk for collagen and
transforming growth factor–beta production and enhanced collagen degradation by matrix metalloproteinase–2.
Conclusions ACE2 inhibits myocardial collagen accumulation and improves LV remodeling and function in a rat model of diabetic cardio-
myopathy. Thus, ACE2 provides a promising approach to the treatment of patients with diabetic cardiomyopathy. (J Am
Coll Cardiol 2012;59:739–47) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.09.071The recent discovery of new family members of the renin-
angiotensin (Ang) system (RAS), such as Ang-converting
enzyme (ACE) 2 (ACE2), Ang-(1-7), and Ang-(1-9), has
From *The Key Laboratory of Cardiovascular Remodeling and Function Research,
Chinese Ministry of Education and Chinese Ministry of Health, Qilu Hospital,
Shandong University, Jinan, Shandong, China; †Department of Cardiology, Shan-
dong Provincial Hospital, Shandong University, Jinan, Shandong, China; ‡Depart-
ment of Medicine, People’s Hospital of Huai Yin District, Jinan, Shandong, China;
and the §Ruijin Hospital, Center of Molecular Medicine, Shanghai Institute of
Endocrinology, State Key Laboratory of Medical Genomics, Shanghai Jiaotong
University School of Medicine, Shanghai, China. All authors have reported that they
have no relationships relevant to the contents of this paper to disclose.
Manuscript received August 9, 2011; accepted September 7, 2011.spurred new research interest in further understanding the
relationship between the RAS and cardiovascular disease
(1). Recently, we found that ACE2 overexpression stabi-
lized atherosclerotic plaque at a late stage and attenuated the
See page 748
progression of atherosclerotic lesions at an early stage in a
rabbit model of atherosclerosis (2,3). Although there is great
enthusiasm for treating heart failure via ACE2 overexpres-
sion, preliminary results are controversial. ACE2-knockout
mice showed severe myocardial contractile dysfunction or no
changes in cardiac dimension or function (4), whereas ACE2
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ACE2-Mitigated Diabetic Cardiomyopathy February 21, 2012:739–47overexpression for 11 weeks in the
myocardium of stroke-prone spon-
taneously hypertensive rats resulted
in marked myocardial fibrosis with
reduced left ventricular (LV) ejec-
tion fraction (LVEF) (5). The
mechanisms underlying these dis-
crepancies are unclear and pending
further investigation.
Diabeticcardiomyopathy(DCM)
is characterized by a variety of
morphological changes, including
myocyte hypertrophy, myofibril de-
pletion, interstitial fibrosis, and in-
tramyocardial microangiopathy.
Among these pathological altera-
tions, myocardial fibrosis is a key
feature of the diabetic heart, and
accumulation of extracellular matrix
(ECM) proteins, particularly in col-
lagen, has been documented. Dys-
regulation of collagen-degrading
matrix metalloproteinases (MMPs)
and tissue inhibitors of metallopro-
teinases (TIMPs) was found to play
an important role in the pathogene-
sis of myocardial fibrosis in diabetes
(6). Singh et al. (7) found that the
intracellular RAS was activated by
high glucose (HG), and the acti-
vated RAS promoted ECM pro-
duction in cardiac myocytes and fi-
broblasts. Westermann et al. (6)
reported that Ang type 1 receptor
antagonists inhibited inflammation
nd matrix accumulation and decreased MMP-2 activity in
CM. On the basis of these experiments, it has been proposed
hat hyperglycemia may activate the RAS, which in turn promotes
ccumulation of ECM and progression of cardiac remodeling and
ysfunction.
ACE2, a homologue of ACE, catalyzes conversion of
ng-II to a vasodilative heptapeptide Ang-(1-7) and con-
ersion of Ang-I to the inactive nonapeptide Ang-(1-9),
hereby functioning effectively as an endogenous ACE
nhibitor. In the present study, we hypothesized that in the
etting of DCM, ACE2 overexpression may inhibit myo-
ardial collagen accumulation and improve LV remodeling
nd function by down-regulation of Ang-II, up-regulation
f Ang-(1-7), and attenuation of ACE expression. A series
f in vitro and in vivo experiments were designed and
erformed to validate this hypothesis.
ethods
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
ACE2  angiotensin-
converting enzyme 2
Ad-ACE2  adenovirus–
angiotensin-converting
enzyme 2
Ad-EGFP  adenovirus–
enhanced green fluorescent
protein
Ang  angiotensin
ARB  angiotensin
receptor blocker
DCM  diabetic
cardiomyopathy
ECM  extracellular matrix
ELISA  enzyme-linked
immunosorbent assay
HG  high glucose
LV  left ventricular
LVEDD  left ventricular
end-diastolic diameter
LVEF  left ventricular
ejection fraction
MMP  matrix
metalloproteinase
RAS  renin-angiotensin
system
TGF  transforming growth
factor
TIMP  tissue inhibitor of
metalloproteinaseee the Online Appendix for details.denoviral vector construction. Murine ACE2 comple-
entary deoxyribonucleic acid was amplified by reverse
ranscription polymerase chain reaction from the ribonucleic
cid of mouse kidney. Recombinant adenoviruses carrying
he murine ACE2 (adenovirus-ACE2 [Ad-ACE2]) or a
ontrol transgene (adenovirus–enhanced green fluorescent
rotein [Ad-EGFP]) were prepared with the AdMax sys-
em (Microbix Biosystems, Toronto, Ontario, Canada).
nimal model and gene transfer. Ninety male Wistar rats
ere first divided into treatment (n  80) and control (n 
0) groups. Rats in the treatment group received a single
ntraperitoneal injection of streptozotocin to induce a dia-
etic status. Then rats in the treatment group were again
ivided into Ad-ACE2, Ad-EGFP, losartan, and mock
roups (n  20 each) (Fig. 1).
CE2 activity assay. ACE2 fluorescence assay was based
n the use of the fluorogenic peptide substrate V (7-Mca-
PPGFSAFK[Dnp]-OH, R&D Systems Inc., Minneapo-
is, Minnesota). Specific ACE2 activity was expressed as
icomoles of substrate converted to the product per unit of
ime and normalized for protein content (units per milli-
ram of protein).
istopathology and immunohistochemistry. The extent
f myocyte hypertrophy was measured on hematoxylin and
osin–stained sections. ACE2, Ang-(1-7), and collagen I
nd III were identified with appropriate antibodies. Mas-
on’s trichrome staining was performed to display collagen
omponents.
estern blot analysis. The protein expression of ACE2,
CE, TIMP-1, MMP-2, MMP-9, and transforming
rowth factor (TGF)- was assayed by Western blot
analysis.
Echocardiography. Left ventricular end-diastolic diameter
(LVEDD), LV end-systolic diameter, LV fractional short-
ening, LVEF, mitral peak flow velocities, and the E/A ratio
were measured using echocardiography.
Hemodynamic measurement. LV systolic pressure, LV
end-diastolic pressure, maximal ascending and descending
rates of LV pressure, and heart rate were measured using
cardiac catheterization.
Zymography. The activity of MMP-2 was evaluated by
zymography.
Real-time reverse transcription polymerase chain reaction.
The messenger ribonucleic acid expression of ACE2 was
quantitated using reverse transcription polymerase chain
reaction.
Enzyme-linked immunosorbent assay (ELISA). ELISA
was performed to measure the levels of Ang-II, Ang-(1-7),
and soluble collagen I and III proteins.
Co-culture of fibroblasts and myocytes. Cardiac fibro-
blasts were co-cultured with Ad-ACE2-transfected or non-
transfected myocytes or the conditioned media of these
cells, and the levels of collagen I and III and TGF-
proteins in the media were determined by ELISA.
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February 21, 2012:739–47 ACE2-Mitigated Diabetic CardiomyopathyHydrogen-3-proline incorporation assay. Hydrogen-3-
proline incorporation study was performed to investigate the
effects of Ad-ACE2 on collagen synthesis.
Statistical analysis. All values are expressed as mean 
SD. Data were evaluated using SPSS version 11.5 (SPSS,
Inc., Chicago, Illinois). A p value 0.05 was considered
significant.
Results
Efficacy of ACE2 gene transfer in vivo. ACE2 messenger
ribonucleic acid and protein expression levels and ACE2
activity showed more than 4-fold increases in the Ad-
ACE2 group compared with the Ad-EGFP or control
group 2 weeks after ACE2 transfection. In contrast, these
measurements were only slightly higher in the losartan
group than in the Ad-EGFP and control groups (p 0.001
o 0.01) (Figs. 2A to 2D).
uantitation of myocyte hypertrophy in vivo. Myocyte
ypertrophy with increased myocyte cross-sectional area
as more prominent in the Ad-EGFP and mock groups
han in the Ad-ACE2 or losartan group, with no significant
ifference between the Ad-EGFP and mock groups or
etween the Ad-ACE2 and losartan groups (p  0.05)
(Figs. 2E and 2F).
Echocardiographic and hemodynamic measurements. At
the end of week 12, LV end-systolic diameters and
LVEDDs were significantly increased, whereas LVEFs, frac-
tional shortening, and E/A ratios were decreased in the mock,
Ad-ACE2, Ad-EGFP, and losartan groups compared with
Figure 1 Flowchart Showing the Timeline of the Experiment
Ad-ACE2  adenovirus–angiotensin-converting enzyme 2; Ad-EGFP  adenovirus–e
STZ  streptozotocin.the control group (all p values0.01) (Online Table 1). At theend of week 16, LV end-systolic diameters and LVEDDs were
significantly decreased, whereas LVEFs, fractional shortening,
and E/A ratios were increased in the Ad-ACE2 and losartan
groups in comparison with the mock and Ad-EGFP groups
(all p values0.01) (Online Table 2), although the differences
etween the Ad-ACE2 and control groups in LVEDD and
VEF were still significant (p  0.05 for both). Importantly,
LVEDD values were higher and LVEF values lower in the
losartan group than in the Ad-ACE2 group (p  0.05).
At the end of week 12, LV end-systolic pressures and the
maximal ascending and descending rates of LV pressure
were substantially decreased, whereas LV end-diastolic
pressures were increased, in the mock, Ad-ACE2, and Ad-
EGFP groups compared with the control group (all p values
0.05) (Online Table 3). At the end of week 16, the maximal
ascending and descending rates of LV pressure were substan-
tially increased, whereas LV end-diastolic pressures were de-
creased, in the Ad-ACE2 and losartan groups in comparison
with the mock and Ad-EGFP groups. However, LVESP was
significantly lower in the losartan group than in the Ad-ACE2,
mock, and Ad-EGFP groups (all p values 0.05) (Online
Table 4).
Collagen and TGF- protein expression in vivo. Cardiac
collagen deposition was lower in the Ad-ACE2 and losartan
groups than in the Ad-EGFP and mock groups (Fig. 3, top
row). Similarly, the protein expression levels of collagen I
(Fig. 3, middle row) and collagen III (Fig. 3, bottom row)
were substantially lower in the Ad-ACE2 and losartan
groups than in the Ad-EGFP and mock groups. In contrast,
ed green fluorescent protein; PBS  phosphate-buffered saline;nhancthe expression levels of total collagen, collagen I, and collagen III
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ACE2-Mitigated Diabetic Cardiomyopathy February 21, 2012:739–47were substantially lower in the Ad-ACE2 group than in the
losartan group (p  0.05). Compared with the Ad-EGFP
and mock groups, the protein expression levels of TGF-
were significantly reduced in the Ad-ACE2 and losartan
groups (Figs. 4A1 and 4A2). However, TGF- protein
expression was still higher in the losartan group than in the
Ad-ACE2 group (p  0.05).
MMP-2 activity and MMP-2, MMP-9, and TIMP-1
protein expression in vivo. MMP-2 activity (Figs. 4B1
and 4B2) and MMP2 protein expression level (Fig. 4C1 and
4C2) were significantly increased in the Ad-ACE2 group in
comparison with the Ad-EGFP and mock groups. MMP-2
activity was higher in the losartan group than in the Ad-EGFP
and mock groups but lower than in the Ad-ACE2 group (p
0.01) (Fig. 4B2). In contrast, the MMP-9 (Figs. 4D1 and
4D2) and TIMP-1 (Figs. 4E1 and 4E2) protein expression
Figure 2 ACE2 Expression and Activity After Gene Transfer in 5
(A) Angiotensin-converting enzyme 2 (ACE2) messenger ribonucleic acid (mRNA) e
expression, and (D) quantitative analysis of ACE2 protein expression by immunos
adenovirus–ACE2 (Ad-ACE2), adenovirus–enhanced green fluorescent protein (Ad-E
staining of cardiomyocytes and (F) quantitative analysis of cardiomyocyte cross-se
Ad-ACE2, Ad-EGFP, mock, and losartan groups of rats. #p  0.05, *p  0.01, andevels were similar among the 4 treatment groups.CE2, ACE, Ang-II, and Ang-(1-7) expression in vivo.
estern blot analysis showed that ACE2 expression was
ncreased significantly in the Ad-ACE2 group compared
ith the Ad-EGFP, losartan, and mock groups (p 0.001)
Figs. 5A and 5B). In contrast, ACE protein expression was
ignificantly lower in the Ad-ACE2 group than in the
d-EGFP, losartan, and mock groups (p  0.01) (Figs. 5C
and 5D). As revealed by ELISA, the Ang-II protein
expression level was lowest in the Ad-ACE2 group and
highest in the losartan group among the 4 treatment groups
(p  0.01) (Fig. 5E). In contrast, the Ang-(1-7) level by
ELISA was significantly higher in the Ad-ACE2 and
losartan groups than in the Ad-EGFP or mock group and
was higher in the Ad-ACE2 group than in the losartan
group (p  0.01 to 0.05) (Fig. 5F).
Ang-II and Ang-(1-7) expression in vitro. Before treat-
ups of Rats
ion, (B) ACE2 activity, (C) representative immunostaining of ACE2 protein
(scale bar  50 m, magnification 40) 2 weeks after gene transfer in
mock, and losartan groups of rats; (E) representative hematoxylin and eosin
l area (scale bar  50 m, magnification 40) 4 weeks after gene transfer in
 0.001 versus Ad-EGFP and mock groups.Gro
xpress
taining
GFP),
ctiona
**pment, Ang-II expression level was higher in the HG group
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February 21, 2012:739–47 ACE2-Mitigated Diabetic Cardiomyopathythan in the normal glucose and osmotic control groups after
12-h and 48-h stimulation of the cardiac fibroblasts (p 
0.01 to 0.05) (Online Fig. 1A) and myocytes (p  0.01)
(Online Fig. 2A). The expression level of Ang-II showed a
time-dependent increase with 12-h, 24-h, and 48-h stimu-
lation after exposure to 25 mmol/l glucose (p  0.01 to
0.05) (Online Figs. 1B and 2B).
After treatment, Ang-II expression level was substantially
lower in the HGAd-ACE2 group than in the HGAd-
EGFP and control groups with the cardiac fibroblasts (Online
Fig. 1C) and myocytes (Online Fig. 2C) at 12 h (p  0.05)
and 48 h (p  0.01). In contrast, the Ang-(1-7) expression
evel was significantly higher in the HGAd-ACE2 group
han in the HGAd-EGFP and control groups at 24 h
p  0.01) (Online Figs. 1D and 2D).
ollagen production in vitro. Collagen synthesis in fibro-
lasts, as evaluated by 3H-proline incorporation, was signif-
icantly reduced in the HGAd-ACE2 group compared
with the HGAd-EGFP or control groups. In contrast,
the administration of A779 in the HGAd-ACE2A779
Figure 3 Masson’s Trichrome Staining of Myocardium and Coll
(Top row) Representative Masson’s trichrome staining of myocardium, (middle ro
adenovirus–angiotensin-converting enzyme 2 (Ad-ACE2), adenovirus–enhanced gre
transfer. The histograms (right) show quantitative analysis of the positive staining
groups; #p  0.05 versus the Ad-ACE2 group. Scale bars  50 m.group resulted in higher levels of collagen protein expressionthan those in the HGAd-ACE2 group (p  0.01)
Online Fig. 3A).
ollagen and TGF- protein expression in fibroblasts in
vitro. ELISA showed that collagen I and III levels were
significantly lower in the HGAd-ACE2 group than in the
HGAd-EGFP or control group, suggesting that Ad-
ACE2 transfection inhibited collagen synthesis in fibro-
blasts. In contrast, collagen I and III levels were signif-
icantly higher in the HGAd-ACE2A779 group than
in the HGAd-ACE2 group (p  0.01) (Online Figs.
3B and 3C).
TGF- protein expression by Western blot analysis was
significantly lower in the HGAd-ACE2 group than in the
HGAd-EGFP and control groups, indicating that Ad-
ACE2 transfection inhibited TGF- expression in fibro-
lasts (p  0.01) (Online Figs. 3D1 and 3D2).
ffects of fibroblast-myocyte co-culture on collagen levels.
he protein levels of collagen I and III were significantly
igher in the fibroblast  nontransfected myocyte group
than in the fibroblast group. In contrast, the protein levels of
Protein Expression in 5 Groups of Rats
unostaining of collagen I, and (bottom row) immunostaining of collagen III in
rescent protein (Ad-EGFP), mock, and losartan groups of rats 4 weeks after gene
llagen, collagen I, and collagen III. *p  0.01 versus the Ad-EGFP and mockagen
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ACE2-Mitigated Diabetic Cardiomyopathy February 21, 2012:739–47transfected myocyte group than in the fibroblast  nontrans-
ected myocyte group (p  0.01) (Online Figs. 4A and 4C).
The protein levels of collagen I and III were substantially
higher in the fibroblast  nontransfected myocyte media
group than in the fibroblast group. In contrast, the protein
levels of collagen I and III were lower in the fibroblast 
ACE2-transfected myocyte media group than in the fibro-
blast  nontransfected myocyte media group (p  0.01)
Online Figs. 4B and 4D).
ffects of fibroblast-myocyte co-culture on TGF-
levels. TGF- levels determined by ELISA were signifi-
antly higher in the fibroblast  nontransfected myocyte
roup than in the fibroblast group. In contrast, TGF-
levels were lower in the fibroblast  ACE2-transfected
yocyte group than in the fibroblast  nontransfected
yocyte group (p  0.01) (Online Fig. 4E).
TGF- levels were substantially higher in the fibroblast 
nontransfected myocyte media group than in the fibro-
blast group. However, TGF- levels were lower in the
Figure 4 TGF-, MMP-2, MMP-9, and TIMP-1 Protein Expressio
(A1) Transforming growth factor (TGF)- protein expression in the myocardium by W
metalloproteinase (MMP)–2 activity in the myocardium by zymographic analysis an
the myocardium by Western blot analysis and (C2) quantitative analysis of the res
sis and (D2) quantitative analysis of the results in (D1); (E1) tissue inhibitor of m
analysis and (E2) quantitative analysis of the results in (E1). *p  0.01 versus a
#p  0.05 versus Ad-EGFP and mock groups. ACE2  angiotensin-converting enzybroblast  ACE2-transfected myocyte media group fihan in the fibroblast  nontransfected myocyte media
roup (p  0.01) (Online Fig. 4F).
ody weight, blood glucose, blood pressure, and heart rate.
ody weight was significantly decreased in rats in the
d-ACE2, Ad-EGFP, losartan, and mock groups from
eek 8 to week 16, whereas blood glucose levels were
ubstantially increased from week 1 to week 16 and did not
iffer among the 4 treatment groups (Online Tables 5 and 6).
t week 16, systolic and diastolic blood pressure were signif-
cantly lower in the losartan group than in the Ad-ACE2,
d-EGFP, and mock groups, but heart rate showed no
ignificant difference among the 4 treatment groups (Online
able 7).
iscussion
he major finding of the present study was that ACE2
verexpression in vitro decreased HG-induced Ang-II pro-
uction and collagen and TGF- expression in cardiac
5 Groups of Rats 4 Weeks After ACE2 Gene Transfer
n blot analysis and (A2) quantitative analysis of the results in (A1); (B1) matrix
quantitative analysis of the results in (B1); (C1) MMP-2 protein expression in
(C1); (D1) MMP-9 protein expression in the myocardium by Western blot analy-
proteinase (TIMP)–1 protein expression in the myocardium by Western blot
irus–enhanced green fluorescent protein (Ad-EGFP) and mock groups;
Ad-ACE2  adenovirus angiotensin-converting enzyme-2.n in
ester
d (B2)
ults in
etallo
denov
me-2;broblasts, and ACE2 overexpression in vivo attenuated
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February 21, 2012:739–47 ACE2-Mitigated Diabetic Cardiomyopathymyocyte hypertrophy, myocardial fibrosis, and LV remod-
eling and improved LV systolic and diastolic function. To
the best of our knowledge, this study is the first to report the
therapeutic effects of ACE2 overexpression in an animal
model of DCM.
The most important pathological feature of DCM is the
accumulation of ECM proteins, particularly in collagen, and
DCM is different from other types of cardiomyopathy in the
lack of an inflammatory response (8). Available evidence
indicates that accumulation of ECM is mediated by hyper-
glycemia, and the RAS plays an important role in collagen
production in DCM (6). Several studies have demonstrated
that Ang-II increases collagen production in cultured car-
diac fibroblasts in vitro. Recently, Singh et al. (7) observed
that inhibition of HG-induced extracellular Ang-II by
candesartan only partially blocked collagen I expression,
whereas inhibition of Ang-II synthesis completely pre-
Figure 5 ACE2, ACE, Ang-(1-7), and Ang-II Protein Expression
(A) Angiotensin (Ang)–converting enzyme (ACE)-2 (ACE2) protein expression in the
(A); (C) ACE protein expression in the myocardium by Western blot analysis and (
enzyme-linked immunosorbent assay (ELISA); (F) Ang-(1-7) levels in the myocardiu
(Ad-EGFP) and mock groups; **p  0.001 versus Ad-EGFP and mock groups; #p 
enzyme-2.vented the HG effects, indicating that both intracellular andextracellular Ang-II levels contribute to enhanced fibrosis
(7). In the present study, ACE2 overexpression lowered
HG-induced Ang-II levels in cardiac fibroblasts and myo-
cytes in vitro and inhibited collagen I and III protein
production in the myocardium of rats in vivo, suggesting
that the major mechanism of ACE2 overexpression in
inhibiting collagen accumulation is probably the conversion
of Ang-II to Ang-1-7.
Cardiac collagen content is regulated by a balance be-
tween collagen production and degradation. Extracellular
degradation of collagen is the major rate limiting step in
collagen metabolism and is affected by MMPs and TIMPs.
Thus, accumulation of myocardial collagen has been re-
garded as a hallmark of myocardial fibrosis, and MMPs and
TIMPs are central to the modulation of ECM composition
in the diabetic heart (7,9). Among identified members of
MMP family, MMP-2 and MMP-9 were found to be
roups of Rats 4 Weeks After ACE2 Gene Transfer
rdium by Western blot analysis and (B) quantitative analysis of the results in
ntitative analysis of the results in (C); (E) Ang-II levels in the myocardium by
LISA. *p  0.01 versus adenovirus–enhanced green fluorescent protein
versus Ad-EGFP and mock groups. Ad-ACE2  adenovirus angiotensin-convertingin 5 G
myoca
D) qua
m by E
0.05essential for collagen degradation. Van Linthout et al. (9)
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ACE2-Mitigated Diabetic Cardiomyopathy February 21, 2012:739–47evaluated the role of matrix MMP-2 in experimental DCM
and found that MMP-2 gene expression and activity were
decreased and associated with ECM accumulation. In the
present study, we found that MMP-2 activity and protein
expression were increased in the Ad-ACE2 group com-
pared with the Ad-EGFP and control groups, but
MMP-9 and TIMP-1 protein expression levels showed
no differences among these groups, suggesting that
ACE2 decreased myocardial collagen accumulation by
up-regulating MMP-2. Our results agree with previous
studies in which MMP-2 activity was down-regulated in
experimental DCM and in cardiac fibroblasts stimulated
by HG and Ang-II (10).
Another important factor regulating collagen production
in DCM is TGF-. Studies in vitro showed that TGF-
exerted a direct effect on cardiac fibroblasts by transforming
these cells into more synthetic myofibroblasts (11). Wester-
mann et al. (6) reported that TGF- expression was
ignificantly increased in DCM, whereas irbesartan, an Ang
ype 1 receptor antagonist, decreased TGF- expression.
Furthermore, in cultured human mesangial cells and cardiac
fibroblasts, HG-induced increase in TGF- production was
artially blocked by the Ang type 1 receptor antagonist
andesartan, which suggests that Ang-II was involved in
GF- production. Our present study showed that TGF-
protein expression was significantly lower in the Ad-ACE2
group than that in the Ad-EGFP and mock groups,
indicating that ACE2 overexpression decreased collagen
production partially through inhibition of TGF- protein
xpression. In view of a recent report that cardiac fibroblasts
nduce myocyte hypertrophy via secretion of paracrine
actors (12), increased collagen and TGF- protein expres-
ion in fibroblasts might contribute to the enhanced car-
iomyocyte hypertrophy observed in the present study. In
ddition, Sarkar et al. (13) showed that myocytes may
ecrete active TGF- in the presence of Ang-II, and
TGF- may induce interleukin-6 production in fibroblasts,
thus promoting collagen synthesis. Our results confirm that
myocytes promoted collagen and TGF- production in
fibroblasts, suggesting that cross-talk between myocytes and
fibroblasts exists, which may play a more important role
than fibroblasts alone in collagen production in DCM.
Current evidence indicates that intracellular Ang-II is an
essential player in diabetes-induced organ damage (14,15).
Singh et al. (7) demonstrated that intracellular Ang-II was
produced in cardiac myocytes and fibroblasts in HG condi-
tions, which up-regulates TGF- and collagen synthesis
nd contributes to ECM accumulation. Although ACE
nhibitors or Ang receptor blockers (ARBs) are effective in
reventing diabetic complications (6,14), recent studies
ound that ARBs can inhibit effects of extracellular rather
han intracellular Ang-II (7). Similarly, ACE inhibitors can
lock Ang-II synthesis catalyzed by ACE, such as in cardiac
broblasts, but cannot block Ang-II synthesis catalyzed by
hymase, such as in cardiac myocytes (7,14,15). Thus,
RBs or ACE inhibitors cannot completely inhibit RAS fctivation in DCM. In contrast, ACE2 catalyzes the
onversion of pro-proliferative Ang-II to antiproliferative
ng-(1-7) in both fibroblasts and myocytes and may
rovide more benefits of cardiac protection than ARBs or
CE inhibitors in the setting of DCM. This concept is
upported by the results of the present study. Although
osartan treatment attenuated myocardial hypertrophy
nd fibrosis and improved LV remodeling and function,
CE2 gene transfer further reduced LVEDD and colla-
en expression and increased LVEF in comparison with
he losartan group, suggesting that ACE2 is probably
ore effective in the treatment of DCM than ARBs. In
ontrast to a previous report that ACE2 deficiency
xhibited diverse effects on the kidney in diabetic mice
16), our results clearly demonstrate the beneficial effects
f ACE2 overexpression on DCM in rats, which is
imilar to the salutary effect of ACE2 in a mouse model
f atherosclerosis observed by the same group of investi-
ators (17).
The putative mechanisms underlying the therapeutic
ffects of ACE2 gene transfer may be 4-fold. First, ACE2
verexpression inhibits collagen accumulation by converting
ng-II to Ang-(1-7) and by enhancing MMP-2 activity.
econd, the balance between ACE and ACE2 is critical for
he functional state of the RAS (18). In the present study,
CE2 overexpression resulted in a shift in balance toward
ow ACE protein expression and hence a low Ang-II
oncentration. Third, the administration of A779 in the
d-ACE2A779 group resulted in one-third higher col-
agen protein expression than the Ad-ACE2 group, indi-
ating that Ang-(1-7) may have a direct inhibitory effect on
ardiac collagen synthesis. Fourth, the most important
echanism of ACE2 in inhibiting collagen accumulation
ay involve suppression of fibroblast-myocyte cross-talk for
ollagen production in the presence of HG.
tudy limitations. First, the rats used in the experiment
ere relatively young (age 24 weeks at euthanasia), whereas
iabetes commonly affects aging population in clinical
ractice. Thus, our results need to be validated in old
iabetic mice. Second, although we found that ACE2
verexpression was associated with down-regulation of
ng-II, up-regulation of Ang-(1-7) and MMP-2 activity,
ttenuation of ACE expression, and inhibition of fibroblast-
yocyte cross-talk, the downstream signaling pathways
ediating the therapeutic effects are unclear and require
urther investigation.
onclusions
ur studies in vitro and in vivo showed that ACE2
verexpression inhibited collagen accumulation and im-
roved LV remodeling and function in a rat model of
CM. The putative mechanisms may involve a shift in
alance toward an inhibited fibroblast-myocyte cross-talk
or collagen and TGF- production and enhanced collagen
d747JACC Vol. 59, No. 8, 2012 Dong et al.
February 21, 2012:739–47 ACE2-Mitigated Diabetic Cardiomyopathydegradation by MMP-2. Thus, ACE2 overexpression may
provide an effective regimen for the treatment of DCM.
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APPENDIX
For an expanded Methods section and supplemental figures and tables,
please see the online version of this article.
